Moleculin Biotech Inc (MBRX): Seemingly conflicting comments in the la...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Moleculin Biotech Inc (MBRX)

Reply Private New

Keep Last Read

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	1
Posts	137
Boards Moderated	0
Alias Born	04/06/2011

Re: ConstitutionNow post# 884

Tuesday, 05/15/2018 10:02:17 AM

Tuesday, May 15, 2018 10:02:17 AM

Seemingly conflicting comments in the latest announcement compared to previous announcements or maybe I dont understand ... can anyone explain?

Today's announcement says they're awaiting approval in Poland:
"We are also awaiting authorization to proceed with our Annamycin clinical trial in Poland, which, if approved by the Polish National Office, would provide a significant and positive expansion of our trial.”
https://ir.moleculin.com/press-releases/detail/85/moleculin-biotech-inc-reports-financial-results-for-the

Then this one back in December 2017 says:
"The protocol approved in Poland allows us to move more aggressively in identifying the optimum dosing for AML patients, which in turn should allow us to move into Phase II data generation more expeditiously."
https://ir.moleculin.com/press-releases/detail/68/moleculin-announces-polish-approval-for-leukemia-clinical

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Keep Last Read

Replies (2) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent MBRX News

Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:00:16 PM
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma • PR Newswire (US) • 09/23/2024 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:31:07 PM
Moleculin Participates in Virtual Investor "What this Means" Segment • PR Newswire (US) • 09/16/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:15:29 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/13/2024 08:15:24 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2024 08:04:30 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:15:12 PM
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma • PR Newswire (US) • 09/09/2024 12:15:00 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/03/2024 09:15:55 PM
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 01:15:00 PM
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar • PR Newswire (US) • 08/26/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:10:01 PM
Moleculin Announces Closing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/19/2024 08:05:00 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/19/2024 02:06:59 PM
Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/16/2024 08:54:18 PM
Moleculin Announces Pricing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/16/2024 12:00:00 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2024 04:15:15 AM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 03:21:01 PM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 01:57:37 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:05:24 PM
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:05:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:00:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:10:26 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 01:05:10 PM

More MBRX News

InvestorsHub NewsWire

North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM

CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM

Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM

Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM

Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM

VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow